Evidence map›Paper›PMID 34466570›Full record

ArticleGalen medical journal2020

Introducing Serine as Cardiovascular Disease Biomarker Candidate via Pathway Analysis.

Mostafa Rezaei Tavirani, Mona Zamanian Azodi, Mohammad Rostami-Nejad, Hamideh Morravej, Zahra Razzaghi, Farshad Okhovatian, Majid Rezaei-Tavirani

Open access · diamondAbstract read
In one paragraph

Article in Galen medical journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Highlighted role of "IL17 signaling pathway" in gastroesophageal reflux disease.Gastroenterology and hepatology from bed to bench · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Mostafa Rezaei TaviraniProteomics Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mona Zamanian AzodiProteomics Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mohammad Rostami-NejadGastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Hamideh MorravejSkin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Zahra RazzaghiLaser Application in Medical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Farshad OkhovatianPhysiotherapy Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Majid Rezaei-TaviraniProteomics Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Shahid Beheshti University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe rate of death due to cardiovascular disease (CVD) is growing. Investigations about CVD that leading to introduce varieties of metabolites is available. The monitoring of these metabolites to find effective ones in the future of clinic applications is the main aim of this study. MATERIALS AND

methodsNumbers of 34 metabolites for the CVD are extracted from literature and designated for interaction determinations by MetScape V 3.1.3. The compound-reaction-enzyme-gene network was constructed and the pathways were analyzed. Based on the presence of metabolites in the pathways the critical compounds were determined.

resultsPathway analysis revealed 18 disturbed pathways related to the CVD. glycerophospholipid metabolism pathway including 27 compounds is related to the 9 queried metabolites. L-Serine which was communed between 5 pathways and also was presented in the largest pathway was identified as the critical compound.

conclusionIt can be concluded that L-Serine is a proper biomarker candidate for CVD diagnosis and also patients follow up approaches.

Indexed as

Cardiovascular DiseasesMetabolic NetworksMetabolome

Identifiers

PMID34466570
PMCPMC8343801
OpenAlexW3010247737

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.